Literature DB >> 35612729

Early surgery: a favorable prognosticator in amiodarone-induced thyrotoxicosis-a single-center experience with 53 cases.

Sohail Bakkar1, Piermarco Papini2, Daniele Cappellani3, Francesco Forfori2, Claudio Di Salvo2, Sonia Catarsi2, Carlo Enrico Ambrosini2, Paolo Miccoli2, Fausto Bogazzi3, Gabriele Materazzi2.   

Abstract

Fewer than 100 cases of amiodarone-induced thyrotoxicosis (AIT) managed surgically have been reported worldwide. This study aims to assess the outcome of thyroidectomy under general anesthesia in a relatively large case series. A retrospective analysis of the clinical records of 53 patients who underwent thyroidectomy for AIT between 1995 and 2019 was conducted. There were 48 (90%) males and 5 females with an average age of 63.7 years. Type 1 and 2 AIT were present in 35 (66%) and 18 (34%) of patients, respectively. The mean preoperative ejection fraction (EF) was 45 ± 13%. Salvage surgery was performed in 6 (11%) patients due to decompensating heart failure and/or malignant arrhythmias. 35 (66%) patients underwent urgent surgery due to a predicted late response to medical therapy and/or the need to discontinue it. Elective surgery was performed in the remainder. A considerable improvement in mean EF occurred 12 months post-surgery (44% vs. 49%; p < 0.001). The overall survival rate following thyroidectomy was 96% at 12 months, and 83% at 5 years. No survival differences were observed based on systolic function. Cardiac-specific mortality was 11%, and these patients demonstrated a considerably shorter survival post-surgery compared to those who died of a non-cardiac cause (27 ± 18 vs. 77.5 ± 54 months; p < 0.05). Total thyroidectomy can be safely performed under general anesthesia despite severe cardiac disease. It considerably improves cardiac function and confers a survival advantage. Therefore, it should be considered early in the treatment plan of select cases.
© 2022. Italian Society of Surgery (SIC).

Entities:  

Keywords:  Amiodarone-induce thyrotoxicosis; Surgical management; Thyroidectomy

Mesh:

Substances:

Year:  2022        PMID: 35612729     DOI: 10.1007/s13304-022-01297-3

Source DB:  PubMed          Journal:  Updates Surg        ISSN: 2038-131X


  7 in total

1.  Amiodarone-induced thyrotoxicosis: clinical presentation and expanded indications for thyroidectomy.

Authors:  D C Mulligan; C R McHenry; W Kinney; C B Esselstyn
Journal:  Surgery       Date:  1993-12       Impact factor: 3.982

Review 2.  The effects of amiodarone on the thyroid.

Authors:  E Martino; L Bartalena; F Bogazzi; L E Braverman
Journal:  Endocr Rev       Date:  2001-04       Impact factor: 19.871

3.  [Hyperthyroidism induced by amiodarone and hyperthyroidism induced by iodine. Histologic, immunohistochemical and ultrastructural aspects].

Authors:  S Guyétant; M C Rousselet; N Wion-Barbot; J C Bigorgne; J Victor; F Dupré; J P Saint André
Journal:  Ann Pathol       Date:  1995       Impact factor: 0.407

Review 4.  Energy-based devices in thyroid surgery-an overview.

Authors:  Sohail Bakkar; Theodosios S Papavramidis; Qusai Aljarrah; Gabriele Materazzi; Paolo Miccoli
Journal:  Gland Surg       Date:  2020-01

5.  [Amiodarone and thyroid function: clinical implications].

Authors:  K Binz; A Burger; M B Vallotton
Journal:  Schweiz Med Wochenschr       Date:  1998-06-27

6.  Is Subacute Thyroiditis an Underestimated Manifestation of SARS-CoV-2 Infection? Insights From a Case Series.

Authors:  Alessandro Brancatella; Debora Ricci; Daniele Cappellani; Nicola Viola; Daniele Sgrò; Ferruccio Santini; Francesco Latrofa
Journal:  J Clin Endocrinol Metab       Date:  2020-10-01       Impact factor: 5.958

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.